|
|
News Breaks
|
February 3, 2012
|
| 09:26 EDT |  | CORT |
| theflyonthewall.com: | Corcept Therapeutics Korlym well-positioned to be approved, says JMP Securities | | JMP Securities believes that the FDA's decision to refrain from holding an Advisory Committee hearing on Corcept's Korlym drug, and the agency's decision not to require a REMs for the drug indicate that the drug will be approved within the next several months. The firm raised its target on Corcept to $9 from $7 and maintains an Outperform rating. :theflyonthewall.com |
|
|
News For CORT From The Last 14 Days Check below for free stories on CORT the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 17:22 EDT |  | CORT |
|
|
|
|
|
Subscribe for More Information